Mode
Text Size
Log in / Sign up
Phase 4 Completed N=7 Randomized Treatment

Varenicline for Co-occurring Cannabis and Tobacco Use

Cannabis Dependence · Tobacco Dependence
Source: ClinicalTrials.gov NCT04595318 ↗
Enrolled (actual)
7
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcomePrimary: Enrollment Rate — 7 Participants
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Pilot, eight week, open-label, within-subject cross over trial of four weeks of standard clinical care (SCC) in an outpatient substance use disorder treatment program and four weeks of SCC and varenicline among current and former tobacco smokers with frequent cannabis use.

Outcome Measures

OutcomeResultp-value
PRIMARY
Enrollment Rate
7
SECONDARY
Retention Rate
7
SECONDARY
Overall Medication Adherence
62
SECONDARY
Number of Participants With Treatment-Emergent Adverse Events: Upset Stomach
5
SECONDARY
Number of Participants With Treatment-Emergent Symptoms of Major Depressive Disorder
1
SECONDARY
Cannabis Craving
34; 35
SECONDARY
Cannabis Withdrawal
4; 4
SECONDARY
Quantity of Cannabis Use
82; 60
SECONDARY
Frequency of Cannabis Use
3; 2
SECONDARY
Number of Cigarettes Smoked Per Day
5; 5
SECONDARY
Number of Participants With Toxicology-verified Cannabis Abstinence
1; 1
SECONDARY
Number of Participants With Biochemically-verified Tobacco Abstinence
2; 1
SECONDARY
Mean Expired Carbon Monoxide
13; 14
SECONDARY
Number of Participants With Treatment-Emergent Suicidal Ideation Events
0; 0

Eligibility Criteria

Inclusion Criteria

  • Able to speak English
  • Uses cannabis at least 5 days in the past 7 days
  • Current or former tobacco smoker
  • Has not taken varenicline in the past 30 days
  • Not pregnant, trying to conceive or breastfeeding
  • Able to provide informed consent
  • Test positive for cannabinoids by urine toxicology

Exclusion Criteria

  • Unstable medical or psychiatric illness
  • Opioid use disorder was initially exclusionary but eligibility criteria were revised after 32 individuals were screened to facilitate recruitment.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04595318). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search